Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis.

CONCLUSION: Daratumumab is associated with lower risk of VTE in clinical trials. PMID: 32710431 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32710431?dopt=Abstract

Source: International Journal of Hematology - July 23, 2020 Category: Hematology Authors: Wang J, Kim Y Tags: Int J Hematol Source Type: research